Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Regulatory News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.75
Bid: 0.65
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.20 (30.769%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

8 Jan 2018 13:26

RNS Number : 2550B
N4 Pharma PLC
08 January 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

N4 PHARMA PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

MYLES MCNULTY

City and country of registered office (if applicable)

 

4. Full name of shareholder(s) (if different from 3.)v

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reachedvi:

05 January 2018

6. Date on which issuer notified (DD/MM/YYYY):

08 January 2018

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

4.34%

 

4.34%

77,142,857

Position of previous notification (if

applicable)

3.97%

 

3.97%

 

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

CA60686A4090

3,345,000

 

4.34%

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

3,345,000

4.34%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

Warrant

 

 

350,000

0.45%

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

350,000

0.45%

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

 

              

 

Place of completion

London

Date of completion

08 January 2018

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFFVLEITIIT
Date   Source Headline
24th Sep 20187:00 amRNSAcceptance of Nuvec® on EUNCL
20th Sep 20187:01 amRNSInterim Results
20th Sep 20187:00 amRNSStrategic Review
30th Jul 201811:05 amRNSSecond Price Monitoring Extn
30th Jul 201811:00 amRNSPrice Monitoring Extension
30th Jul 20187:00 amRNSChange of Adviser
17th Jul 20181:12 pmRNSHolding(s) in Company
11th Jul 20182:05 pmRNSSecond Price Monitoring Extn
11th Jul 20182:00 pmRNSPrice Monitoring Extension
9th Jul 20187:00 amRNSClinical trials preliminary results
18th Jun 20187:00 amRNSNuvec® Update
23rd May 201811:31 amRNSResult of AGM
9th May 20187:00 amRNSFiling of Patent
27th Apr 201811:00 amRNSPosting of Annual Report and Notice of AGM
25th Apr 20187:00 amRNSFinal Results
18th Apr 20187:00 amRNSCommencement of Sildenafil Clinical Trial
9th Apr 201811:00 amRNSPrice Monitoring Extension
9th Mar 20188:43 amRNSExercise of Warrants and Total Voting Rights
8th Mar 201810:05 amRNSHolding(s) in Company
8th Mar 20187:00 amRNSNuvec® Update
7th Mar 20188:33 amRNSExercise of Warrants and Total Voting Rights
2nd Mar 201812:17 pmRNSChange of Adviser
26th Feb 20189:27 amRNSExercise of Warrants and Total Voting Rights
21st Feb 20181:36 pmRNSExercise of Warrants and Total Voting Rights
19th Feb 20185:01 pmRNSExercise of Warrants and Total Voting Rights
14th Feb 20185:26 pmRNSExercise of Warrants and Total Voting Rights
13th Feb 201812:52 pmRNSExercise of Warrants and Total Voting Rights
12th Feb 20182:05 pmRNSSecond Price Monitoring Extn
12th Feb 20182:00 pmRNSPrice Monitoring Extension
12th Feb 201811:06 amRNSSecond Price Monitoring Extn
12th Feb 201811:00 amRNSPrice Monitoring Extension
8th Feb 201812:01 pmRNSHolding(s) in Company
8th Feb 201811:46 amRNSExercise of Warrants and Total Voting Rights
5th Feb 20187:00 amRNSIssue of Equity and Director/PDMR Shareholding
2nd Feb 20184:47 pmRNSExercise of Warrants and Total Voting Rights
2nd Feb 20181:04 pmRNSAward of Grant and Collaboration with MedImmune UK
30th Jan 20183:04 pmRNSExercise of Warrants and Total Voting Rights
24th Jan 20184:06 pmRNSExercise of Warrants and Total Voting Rights
24th Jan 20181:19 pmRNSGlobal Business Accelerator Programme in Japan
22nd Jan 201810:44 amRNSExercise of Warrants and Total Voting Rights
15th Jan 201812:36 pmRNSHolding(s) in Company
8th Jan 20182:31 pmRNSExercise of Warrants and Total Voting Rights
8th Jan 20181:26 pmRNSHolding(s) in Company
28th Dec 20179:03 amRNSExercise of Warrants and Total Voting Rights
22nd Dec 20177:00 amRNSFiling of Patent
18th Dec 20178:27 amRNSHolding(s) in Company
13th Dec 20174:07 pmRNSExercise of Warrants and Total Voting Rights
29th Nov 201711:12 amRNSViagra switch to OTC status in the UK
10th Nov 20174:04 pmRNSDirector/PDMR Shareholding
8th Nov 20177:00 amRNSResults of latest nuvec pre-clinical study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.